6,8-bis(benzylthio)octanoic acid

DRUG11 trials

Sponsors

Wake Forest University Health Sciences

Conditions

Acinar Cell Adenocarcinoma of the PancreasAdult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaAdult Nodular Sclerosis Hodgkin LymphomaAdult Primary Cholangiocellular CarcinomaAdvanced Adult Primary Liver Cancer

Phase 1

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

CompletedNCT01766219

Wake Forest University Health SciencesAdult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct +6

Start: 2013-05-31End: 2018-05-18Updated: 2019-05-15

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

CompletedNCT01835041

Wake Forest University Health SciencesAcinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer +1

Start: 2013-04-30End: 2023-03-16Updated: 2023-07-12

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

CompletedNCT01839981

Wake Forest University Health SciencesAcinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer +2

Start: 2013-07-31End: 2015-10-31Updated: 2018-12-27

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

CompletedNCT01931787

Wake Forest University Health SciencesRecurrent Small Cell Lung Cancer

Start: 2013-10-31End: 2015-12-31Updated: 2018-07-03

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

TerminatedNCT02168907

Wake Forest University Health SciencesB-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma +24

Start: 2014-12-31End: 2015-02-28Updated: 2018-07-02

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

CompletedNCT02168140

Wake Forest University Health SciencesAdult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma +14

Start: 2014-09-30End: 2022-09-15Updated: 2024-02-13

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

CompletedNCT02232152

Wake Forest University Health SciencesMucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer +13

Start: 2015-01-06End: 2023-01-11Updated: 2023-08-07

6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

WithdrawnNCT02472626

Wake Forest University Health SciencesUntreated Adult Acute Myeloid Leukemia

Start: 2015-12-31End: 2016-07-31Updated: 2018-07-03

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

CompletedNCT02484391

Wake Forest University Health SciencesGranulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia

Start: 2015-09-30End: 2022-02-02Updated: 2024-09-19

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

WithdrawnNCT03370159

Wake Forest University Health SciencesStage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7

Start: 2018-06-30End: 2020-03-01Updated: 2018-08-01

Phase 2

CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy

TerminatedNCT01902381

Wake Forest University Health SciencesPreviously Treated Myelodysplastic Syndromes

Start: 2013-08-31End: 2018-11-26Updated: 2024-10-17

Related Papers

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia

Nature Communications2022-03-3040 citations

A phase I clinical trial of fluorouracil (5-FU) + devimistat (CPI-613) combination in previously treated patients (pts) with metastatic colorectal cancer (MCR).

Journal of Clinical Oncology2019-05-203 citations

Anti-mitochondrial therapy in bile duct cancer.

Journal of Clinical Oncology2017-05-201 citations

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.

2017-05-08182 citations

Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Blood2016-12-027 citations

Pilot study of first-in-class antimitochondrial metabolism agent, CPI-613, as salvage monotherapy for small cell lung cancer.

Journal of Clinical Oncology2016-05-201 citations

The mitochondrial metabolism inhibitor CPI-613 in combination with mFOLFIRINOX for pancreatic adenocarcinoma.

Journal of Clinical Oncology2016-02-01